

Antonio Vitale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9321506/publications.pdf>

Version: 2024-02-01

117
papers

3,429
citations

117625

34
h-index

189892

50
g-index

118
all docs

118
docs citations

118
times ranked

2661
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. <i>Clinical Rheumatology</i> , 2022, 41, 641-647.	2.2	6
2	Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. <i>Rheumatology</i> , 2022, 61, 4124-4129.	1.9	16
3	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis. <i>Ophthalmology and Therapy</i> , 2022, 11, 899-911.	2.3	14
4	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis. <i>Ophthalmology and Therapy</i> , 2022, 11, 887-897.	2.3	9
5	Effectiveness of rituximab in bullous Sweet's syndrome. <i>International Journal of Dermatology</i> , 2022, , .	1.0	2
6	Development and Implementation of the AIDA International Registry for Patients With Still's Disease. <i>Frontiers in Medicine</i> , 2022, 9, 878797.	2.6	9
7	Retention rate of IL-1 inhibitors in Schnitzler's syndrome.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
8	Adult-onset Still's disease with elderly onset, results from a multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	5
9	Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110371.	2.7	1
10	Effectiveness of SB5, an Adalimumab Biosimilar, in Patients With Noninfectious Uveitis: A Real-Life Monocentric Experience. <i>Asia-Pacific Journal of Ophthalmology</i> , 2021, 10, 360-365.	2.5	14
11	Clinical profile and evolution of patients with juvenile-onset Behçet's syndrome over a 25-year period: insights from the AIDA network. <i>Internal and Emergency Medicine</i> , 2021, 16, 2163-2171.	2.0	8
12	Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry. <i>Rheumatology</i> , 2021, 60, 5705-5712.	1.9	4
13	The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile. <i>Scientific Reports</i> , 2021, 11, 12455.	3.3	10
14	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome's Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. <i>Frontiers in Medicine</i> , 2021, 8, 668173.	2.6	6
15	Resolution of Schnitzler's syndrome after haematopoietic stem cell transplantation. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 704.	0.8	0
16	Resolution of Schnitzler's syndrome after haematopoietic stem cell transplantation. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 704-704.	0.8	3
17	The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 298-304.	1.8	46
18	Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF- α inhibition: a narrative review. <i>Clinical Rheumatology</i> , 2020, 39, 327-337.	2.2	12

#	ARTICLE	IF	CITATIONS
19	Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease. <i>Mediators of Inflammation</i> , 2020, 2020, 1-7.	3.0	18
20	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF- α Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. <i>Mediators of Inflammation</i> , 2020, 2020, 1-12.	3.0	24
21	Safety of systemic treatments for Behçet's syndrome. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1269-1301.	2.4	6
22	Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. <i>Mediators of Inflammation</i> , 2020, 2020, 1-6.	3.0	7
23	Long-Term Outcomes of Behçet's Syndrome-Related Uveitis: A Monocentric Italian Experience. <i>Mediators of Inflammation</i> , 2020, 2020, 1-8.	3.0	12
24	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020, 7, 42.	2.6	21
25	Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. <i>Inflammopharmacology</i> , 2020, 28, 711-718.	3.9	19
26	Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. <i>Internal and Emergency Medicine</i> , 2020, 15, 1031-1039.	2.0	13
27	Efficacy of monoclonal anti-tumour necrosis factor- α antibodies in uveitic macular oedema. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 621-625.	0.8	0
28	Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. <i>Clinical Rheumatology</i> , 2019, 38, 407-415.	2.2	56
29	Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1405-1411.	0.9	44
30	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 918.	3.5	25
31	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019, 10, 296.	3.5	35
32	Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1898.	4.1	60
33	Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. <i>Mediators of Inflammation</i> , 2019, 2019, 1-8.	3.0	27
34	The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors. <i>Frontiers in Pharmacology</i> , 2019, 10, 1468.	3.5	19
35	Hints for Genetic and Clinical Differentiation of Adult-Onset Monogenic Autoinflammatory Diseases. <i>Mediators of Inflammation</i> , 2019, 2019, 1-29.	3.0	17
36	Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet's Disease. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 58-63.	1.8	40

#	ARTICLE	IF	CITATIONS
37	Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 34-39.	1.8	37
38	Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. <i>Clinical Rheumatology</i> , 2019, 38, 63-70.	2.2	29
39	Efficacy of anti-tumour necrosis factor- α monoclonal antibodies in patients with non-infectious anterior uveitis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 301-305.	0.8	8
40	Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 680-683.	0.8	19
41	Differential serum levels of interleukin-37 in patients with tumour necrosis factor receptor-associated periodic syndrome (TRAPS). <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 121, 159-160.	0.8	0
42	Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 1500-1507.	5.6	57
43	Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab. <i>Clinical Rheumatology</i> , 2018, 37, 1715-1720.	2.2	21
44	Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study. <i>British Journal of Ophthalmology</i> , 2018, 102, 637-641.	3.9	44
45	Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behçet's disease. <i>Immunology Letters</i> , 2018, 201, 38-44.	2.5	24
46	Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. <i>Clinical Rheumatology</i> , 2018, 37, 2805-2809.	2.2	35
47	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2018, 37, 2233-2240.	2.2	64
48	Musculoskeletal manifestations in hereditary periodic fever syndromes. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 110, 25-31.	0.8	0
49	The eye involvement in monogenic autoinflammatory diseases: literature review and update. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 110, 44-53.	0.8	4
50	Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with Behçet's Disease. <i>Israel Medical Association Journal</i> , 2018, 20, 517-521.	0.1	3
51	Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. <i>Israel Medical Association Journal</i> , 2018, 20, 438-441.	0.1	7
52	Serum immunoglobulin D levels in patients with Behçet's disease according to different clinical manifestations. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 110-115.	0.8	8
53	Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 34-44.	6.5	14
54	A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome. <i>Clinical Rheumatology</i> , 2017, 36, 463-468.	2.2	64

#	ARTICLE	IF	CITATIONS
55	Canakinumab efficacy in refractory adult-onset PFAPA syndrome. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1050-1051.	1.9	31
56	Challenges and new horizons in the periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 165-171.	0.8	14
57	Certolizumab Pegol treatment in Behçet's disease with different organ involvement: A multicenter retrospective observational study. <i>Modern Rheumatology</i> , 2017, 27, 1031-1035.	1.8	38
58	The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experience from a referral center in Italy. <i>Internal and Emergency Medicine</i> , 2017, 12, 605-611.	2.0	13
59	Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease. <i>Clinical Rheumatology</i> , 2017, 36, 2063-2069.	2.2	36
60	Quality of life impairment in Behçet's disease and relationship with disease activity: a prospective study. <i>Internal and Emergency Medicine</i> , 2017, 12, 947-955.	2.0	46
61	Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 549-555.	1.4	11
62	Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature. <i>Clinical Rheumatology</i> , 2017, 36, 1687-1690.	2.2	22
63	Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2017, 36, 191-197.	2.2	115
64	Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet's disease uveitis and concomitant bladder papillary carcinoma. <i>Internal Medicine Journal</i> , 2017, 47, 1086-1088.	0.8	11
65	Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2017, 36, 183-189.	2.2	84
66	Auditory involvement in Behçet's disease: relationship with demographic, clinical, and therapeutic characteristics. <i>Clinical Rheumatology</i> , 2017, 36, 445-449.	2.2	9
67	Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2017, 36, 451-455.	2.2	52
68	Interleukin-1 blockade in neurobehçet's disease: a case-based reflection. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1046-1049.	1.9	11
69	Diagnostic Criteria for Adult-Onset Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome. <i>Frontiers in Immunology</i> , 2017, 8, 1018.	4.8	37
70	Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 93-97.	0.8	7
71	Circulating intercellular adhesion molecule 1 (sICAM-1) in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 104, 13-14.	0.8	0
72	Evolving Frontiers in the Treatment of Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA) Syndrome. <i>Israel Medical Association Journal</i> , 2017, 19, 444-447.	0.1	15

#	ARTICLE	IF	CITATIONS
73	Impact of Uveitis on Quality of Life: A Prospective Study from a Tertiary Referral Rheumatology-Ophthalmology Collaborative Uveitis Center in Italy. Israel Medical Association Journal, 2017, 19, 478-483.	0.1	19
74	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Frontiers in Pharmacology, 2016, 7, 380.	3.5	72
75	New therapeutic solutions for Behçet's syndrome. Expert Opinion on Investigational Drugs, 2016, 25, 827-840.	4.1	36
76	Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. Clinical Rheumatology, 2016, 35, 2631-2638.	2.2	28
77	Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases. Expert Opinion on Biological Therapy, 2016, 16, 1311-1312.	3.1	30
78	PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. Clinical Rheumatology, 2016, 35, 501-505.	2.2	28
79	Lights and shadows in autoinflammatory syndromes from the childhood and adulthood perspective. Clinical Rheumatology, 2016, 35, 565-572.	2.2	9
80	Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives. Current Rheumatology Reports, 2016, 18, 3.	4.7	55
81	Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. Clinical Rheumatology, 2016, 35, 1281-1286.	2.2	95
82	Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection. Clinical and Experimental Rheumatology, 2016, 34, 353.	0.8	7
83	Interleukin-1 Inhibition in Behçet's disease. Israel Medical Association Journal, 2016, 18, 171-6.	0.1	26
84	One year in review 2016: novelties in the treatment of rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 357-72.	0.8	17
85	Demographic, clinical and therapeutic findings in a monocentric cohort of adult patients with suspected PFAPA syndrome. Clinical and Experimental Rheumatology, 2016, 34, 77-81.	0.8	21
86	Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M <sc>TNFRSF1A</sc> variant. International Journal of Rheumatic Diseases, 2015, 18, 473-475.	1.9	5
87	Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. Journal of Medical Case Reports, 2015, 9, 123.	0.8	28
88	Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. Mediators of Inflammation, 2015, 2015, 1-10.	3.0	22
89	Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives. Mediators of Inflammation, 2015, 2015, 1-21.	3.0	79
90	Anakinra treatment in drug-resistant Behçet's disease: a case series. Clinical Rheumatology, 2015, 34, 1293-1301.	2.2	114

#	ARTICLE	IF	CITATIONS
91	Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease. <i>Clinical Rheumatology</i> , 2015, 34, 1817-1820.	2.2	29
92	Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). <i>Rheumatology International</i> , 2015, 35, 1943-1947.	3.0	39
93	The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. <i>Clinical Rheumatology</i> , 2015, 34, 17-28.	2.2	37
94	Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. <i>Clinical Rheumatology</i> , 2015, 34, 807-809.	2.2	20
95	One year in review 2015: Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 259-71.	0.8	30
96	Adult-onset tumour necrosis factor receptor-associated periodic syndrome presenting with refractory chronic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S171-2.	0.8	6
97	Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders. <i>Israel Medical Association Journal</i> , 2015, 17, 93-7.	0.1	18
98	Untangling the Web of Systemic Autoinflammatory Diseases. <i>Mediators of Inflammation</i> , 2014, 2014, 1-15.	3.0	25
99	Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Behçet's Disease: A Case Series. <i>Dermatology</i> , 2014, 228, 211-214.	2.1	74
100	The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: Clinical manifestations and long-term follow-up. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 818-823.	3.4	71
101	Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. <i>Autoimmunity Reviews</i> , 2014, 13, 1220-1229.	5.8	86
102	Serum amyloid-A in Behçet's disease. <i>Clinical Rheumatology</i> , 2014, 33, 1165-1167.	2.2	14
103	Working the endless puzzle of hereditary autoinflammatory disorders. <i>Modern Rheumatology</i> , 2014, 24, 381-389.	1.8	20
104	The hereditary autoinflammatory disorders uncovered. <i>Autoimmunity Reviews</i> , 2014, 13, 892-900.	5.8	53
105	Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. <i>Clinical Rheumatology</i> , 2014, 33, 1197-1207.	2.2	58
106	Diagnosis and classification of relapsing polychondritis. <i>Journal of Autoimmunity</i> , 2014, 48-49, 53-59.	6.5	77
107	Biological Treatments: New Weapons in the Management of Monogenic Autoinflammatory Disorders. <i>Mediators of Inflammation</i> , 2013, 2013, 1-16.	3.0	64
108	Monogenic Autoinflammatory Syndromes: State of the Art on Genetic, Clinical, and Therapeutic Issues. <i>International Journal of Rheumatology</i> , 2013, 2013, 1-15.	1.6	67

#	ARTICLE	IF	CITATIONS
109	The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 141-9.	0.8	24
110	Rare NLRP12 variants associated with the NLRP12-autoinflammatory disorder phenotype: an Italian case series. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 155-6.	0.8	31
111	Clinical and biochemical landmarks in systemic autoinflammatory diseases. <i>Annals of Medicine</i> , 2012, 44, 664-673.	3.8	34
112	The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: Our experience and review of the literature. <i>Autoimmunity Reviews</i> , 2012, 12, 10-13.	5.8	47
113	Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. <i>Clinical Research in Cardiology</i> , 2012, 101, 525-531.	3.3	97
114	Diagnosis of PFAPA syndrome applied to a cohort of 17 adults with unexplained recurrent fevers. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 269-71.	0.8	48
115	A case of resistant adult-onset periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome responsive to anakinra. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 593.	0.8	37
116	Long-term clinical course of patients carrying the Q703K mutation in the NLRP3 gene: a case series. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 943-6.	0.8	29
117	Retention rate of IL-1 inhibitors in Schnitzler's syndrome. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	3